Effects of hexoprenaline on cyclic AMP content and on activities of adenyl cyclase of lung, liver and heart in rats

Ikegami, K.; Hirano, S.; Imamura, H.

Yakugaku Zasshi Journal of the Pharmaceutical Society of Japan 96(9): 1122-1126


ISSN/ISBN: 0031-6903
PMID: 185352
Accession: 068523305

Download citation:  

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

The effect of hexoprenaline (ST-1512), a selective .beta.2-adrenergic stimulant, on cyclicAMP [cAMP] content in slices of the lung, liver and heart of rats and on the adenylate cyclase activity was examined. Maximum increase of cAMP in slices caused by hexoprenaline was observed in order of the lung (300%), liver (230%) and heart (60%), while that with DL-isoproterenol was in the order of the lung (490%), heart (375%) and liver (270%). The concentration (PC50) of hexoprenaline which gives half maximal increase of cAMP was approximately equal to that of isoproterenol in the lung and liver, but was larger than that in the heart. The increase of cAMP content in the liver by hexoprenaline was inhibited by .beta.-blockers such as bufetolol and practolol. Hexoprenaline stimulated adenylate cyclase of the tissues tested. The order of maximum increase in the liver and heart caused by hexoprenaline and isoproterenol was the same as that of the cAMP content in slices, and PC50 of both compounds for the stimulation of adenylate cyclase was close to those of cAMP content in the liver and heart. The stimulation of liver adenylate cyclase by hexoprenaline was blocked by bufetolol. The selective .beta.2-adrenergic stimulating activity of hexoprenaline may be attributable to the increase in cAMP content resulting from the selective stimulation of adenylate cyclase of the tissues which have .beta.2-adrenergic receptors.